Glaxo Sued Over Myodil

12 December 1994

Glaxo of the UK is being sued by some 400 patients who were injected with a medical dye manufactured by Glaxo.

Most of the patients were injected with the dye between 1944 and 1987, when it was used in spinal X-rays. The patients are saying that the dye stayed in the spine for several years and caused inflammation, damaged nerves and acute pain.

It is also alleged that Glaxo did not issue adequate warnings about side effects. Glaxo is denying negligence and has said that the side effects of the product were well documented.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight